OTCM
WXXWY
Market cap29bUSD
Oct 07, Last price
14.43USD
1D
-2.43%
1Q
52.38%
IPO
308.01%
Name
WuXi Biologics (Cayman) Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Related entities
Subsidiaries
WuXi Biologics (Hong Kong) Limited
Key people
Ge Li
Non-Executive Chairman of the Board · since 2014
Zhisheng Chen
Chief Executive Officer, Executive Director · since 2016
Ming Tu
Chief Financial Officer · since 2021
Jian Dong
Chief Executive Officer - WuXi Vaccines · since 2024
Senior Vice President - Global Manufacturing · since 2020
Wei Guo
Senior Vice President and Head of Global Manufacturing Department · since 2024
Juergen Hinderer
Senior Vice President - Head of Global Engineering Department · since 2024
Hou Loh Ing
Senior Vice President, Head - Global Quality Department · since 2023
Keqiang Shen
Senior Vice President, Head - China Biomanufacturing · since 2020
Angus Turner
Senior Vice President - Global Business Development and Alliance Management · since 2020
Jijie Gu
President - Global Biologics Research, Chief Scientific Officer · since 2023
Xuejun Gu
Executive Director · since 2025
Xuejun Gu
Executive Director · since 2025
Yue Huang
Joint Company Secretary · since 2018
Ying Man Sham
Joint Company Secretary · since 2019
Non-Executive Director · since 2016
Miao Jingwen
Non-Executive Director · since 2024
Jue Chen
Non-Executive Independent Director · since 2023
Kenneth Hitchner
Non-Executive Independent Director · since 2020
Non-Executive Independent Director · since 2017
Legal address
PO Box 309
Ugland House
George Town KY1-1104
KY
Ugland House
George Town KY1-1104
KY
Headquarters
12th Floor
4 New York Plaza
New York, NY 10004
US
4 New York Plaza
New York, NY 10004
US
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||